differentiated anti-BCMA autologous CAR T cells ARI0002h

{
  "id": "MLC-T-ONC-013048",
  "term": "differentiated anti-BCMA autologous CAR T cells ARI0002h",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of adult human differentiated autologous T lymphocytes that have been ex vivo expanded and transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, the differentiated anti-BCMA autologous CAR T cells ARI0002h specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.",
  "synonyms": [
    "CARTBCMA ARI0002h",
    "autologous differentiated anti-BCMA CAR T-cells ARI0002h"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/differentiated-anti-bcma-autologous-car-t-cells-ari0002h/"
}